Get the Stockscreener App
7.48
1.19%
-0.09
Pre-market:
7.43
-0.05
-0.67%
Puma Biotechnology Inc stock is traded at $7.48, with a volume of 262.82K.
It is down -1.19% in the last 24 hours and up +26.78% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$7.57
Open:
$7.56
24h Volume:
262.82K
Relative Volume:
0.66
Market Cap:
$380.56M
Revenue:
$228.37M
Net Income/Loss:
$31.11M
P/E Ratio:
12.25
EPS:
0.6108
Net Cash Flow:
$41.73M
1W Performance:
-0.40%
1M Performance:
+26.78%
6M Performance:
+36.00%
1Y Performance:
+152.70%
1-Day Range:
$7.44
$7.645
1-Week Range:
$7.38
$7.8983
52-Week Range:
$2.75
$7.8983
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
7.48 | 385.14M | 228.37M | 31.11M | 41.73M | 0.6108 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotechnology stock declines more than 9% in a month: Here's why - MSN
Ritholtz Wealth Management Boosts Stake in Puma Biotechnology - National Today
Puma Biotechnology, Inc. $PBYI Shares Acquired by Ritholtz Wealth Management - MarketBeat
What Do Analysts Think About Puma Biotechnology (PBYI)? - MSN
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Puma Biotechnology Stock Surges Past 200-Day Average - National Today
Puma Biotechnology (NASDAQ: PBYI) seeks votes to extend CEO warrant, elect directors - Stock Titan
Can Puma Biotechnology Inc sustain its profitabilityWeekly Stock Analysis & Real-Time Market Trend Scan - baoquankhu1.vn
PBYI PE Ratio & Valuation, Is PBYI Overvalued - Intellectia AI
Investor Mood: Is Puma Biotechnology Inc undervalued by DCF analysisWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 - BioSpace
Puma Biotechnology reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Pharma News: Is Puma Biotechnology Inc a momentum stockAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Recap Report: What is Puma Biotechnology Incs 5 year growth outlook2026 Technicals & Low Risk Growth Stock Ideas - baoquankhu1.vn
Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially - Investing.com
Earnings call transcript: Puma Biotechnology Inc. reports strong Q4 2025 results - in.investing.com
Vanguard disaggregates holdings; Puma Biotechnology (PBYI) shows 0 shares reported - stocktitan.net
Forecast Cut: Is Puma Biotechnology Inc a momentum stockPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
Rate Hike: Can Puma Biotechnology Inc be the next market leaderPortfolio Update Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy - MarketBeat
Shorts Report: Is Puma Biotechnology Inc undervalued by DCF analysis2026 Trading Volume Trends & Reliable Price Breakout Signals - baoquankhu1.vn
Whats the MACD signal for Puma Biotechnology Inc2026 Market WrapUp & Weekly Setup with ROI Potential - baoquankhu1.vn
Earnings Miss: Can Puma Biotechnology Inc be the next market leaderQuarterly Trade Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - Yahoo Finance
Buy Signal: Is Puma Biotechnology Inc trading at a discount2026 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
Puma Biotechnology Stock Crosses 200-Day Moving Average - National Today
Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView
Published on: 2026-03-12 08:35:52 - baoquankhu1.vn
Puma Biotech (PBYI) Earnings Call Transcript - AOL.com
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen - marketbeat.com
PBYI Q4 earnings & sales beat estimates, stock down on weak 2026 view - MSN
Puma Biotechnology, Inc. (PBYI) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Puma Biotech at TD Cowen Conference: Strategic Growth and Financial Discipline - Investing.com Canada
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2025 Earnings Call Transcript - Insider Monkey
PBYI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by Wall Street Zen - MarketBeat
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View - The Globe and Mail
PBYI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Puma Biotechnology Hits New 52-Week High of $7.68, Up 120% - Markets Mojo
Puma Biotechnology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-02-27 - Seeking Alpha
Earnings call transcript: Puma Biotechnology Q4 2025 beats forecasts with strong revenue growth - Investing.com India
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Puma Biotechnology Q4 Earnings Call Highlights - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):